Key Points
- Biodesix Director Jack Schuler bought 13,700 shares at an average price of $24.01, investing approximately $328,937 and increasing his direct ownership by 2.6% to 540,810 shares.
- Biodesix reported a quarterly loss of $0.71 per share, beating estimates by $0.19, while revenue of $26.86 million also exceeded analyst expectations.
- Analyst sentiment is broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $31.33 versus its $24.22 opening price.
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler purchased 13,700 shares of the stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $24.01 per share, with a total value of $328,937.00. Following the completion of the purchase, the director directly owned 540,810 shares of the company's stock, valued at $12,984,848.10. The trade was a 2.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
Biodesix Stock Performance
NASDAQ BDSX opened at $24.22 on Thursday. The company has a 50-day simple moving average of $20.19 and a two-hundred day simple moving average of $16.05. Biodesix, Inc. has a 12-month low of $5.26 and a 12-month high of $25.52. The firm has a market cap of $255.52 million, a price-to-earnings ratio of -7.64 and a beta of 0.56. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12.
Biodesix (NASDAQ:BDSX - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.19. The company had revenue of $26.86 million during the quarter, compared to analyst estimates of $26.03 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. On average, equities analysts forecast that Biodesix, Inc. will post -2.68 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in BDSX. AIGH Capital Management LLC purchased a new stake in shares of Biodesix in the 1st quarter worth about $10,996,000. XTX Topco Ltd lifted its position in Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares during the period. Walleye Capital LLC bought a new stake in Biodesix during the 2nd quarter valued at about $1,679,000. Stempoint Capital LP purchased a new position in shares of Biodesix in the first quarter worth $1,015,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Biodesix during the second quarter valued at $1,060,000. 20.96% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
BDSX has been the subject of several recent analyst reports. Roth Capital started coverage on shares of Biodesix in a research note on Wednesday, June 24th. They set a "buy" rating and a $32.00 price objective for the company. Weiss Ratings upgraded Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, June 12th. Canaccord Genuity Group upped their price target on Biodesix from $27.00 to $35.00 and gave the company a "buy" rating in a research report on Monday. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective (up from $26.00) on shares of Biodesix in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.33.
Get Our Latest Stock Analysis on Biodesix
Biodesix Company Profile
(
Get Free Report)
Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.
The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
